Why yesterday’s perfect dose may not produce tomorrow’s perfect response.

There’s an interesting little conversation that happens in cannabinoid medicine, and it usually begins with someone saying, “I’ve been taking the same amount for months, but it doesn’t seem to work like it used to.”

The natural response is to increase the dose. After all, if five milligrams worked before and five milligrams isn’t producing the same effect now, perhaps ten milligrams will solve the problem. Sometimes a dose adjustment is appropriate, but there’s another possibility worth investigating before we start pouring more into the equation.

What if the medicine hasn’t changed, but the biology receiving it has?

In the previous article, we explored why two people can respond differently to the same cannabinoid product. Genetics, metabolism, medications, previous exposure and individual physiology all influence the experience. But biology doesn’t stop adapting once we’ve established a dose that works. Repeated exposure can change how the body responds to that very same substance.

This is called tolerance, and it isn’t unique to cannabis. We see versions of it with caffeine, alcohol, certain medications and numerous other substances. The nervous system is particularly good at adjusting to repeated chemical signals. Sometimes those adjustments are protective, sometimes they reduce a desired effect, and sometimes they introduce complications nobody ordered.

The important distinction is that tolerance doesn’t necessarily mean a substance has stopped interacting with the body. It means that a particular effect has diminished after repeated exposure. The compound may still be present, receptors may still be activated, and biological processes may still be changing. What has changed is the relationship between the dose and the response.

That’s adaptation, and the endocannabinoid system provides a particularly interesting example.

When Receptors Learn the Routine

THC produces many of its effects through CB1 receptors, which are especially abundant in the brain and nervous system. These receptors normally participate in signaling involving our own endocannabinoids, including anandamide (AEA) and 2-arachidonoylglycerol (2-AG). THC enters that existing communication network and activates CB1 receptors, although its signaling characteristics differ from those of the body’s own cannabinoids.

With repeated THC exposure, cells can begin adjusting their response. One mechanism is receptor desensitization, in which a receptor becomes less effective at transmitting a signal. Another is downregulation, in which the number of receptors available for signaling decreases. Both mechanisms can contribute to cannabinoid tolerance, although the extent varies by brain region, exposure pattern and the particular effect being measured.

Think of it like living beside a busy road. During the first few nights, every passing truck gets your attention. Months later, you may barely notice the traffic. The trucks haven’t disappeared. Your nervous system has adjusted to a repeated signal.

Biology is remarkably good at deciding which messages deserve its attention.

And sometimes that ability becomes inconvenient when the signal we’re adapting to is one we’re intentionally using for relief.

Human brain-imaging research has demonstrated that chronic daily cannabis use is associated with reduced CB1 receptor availability in certain brain regions. Importantly, studies have also observed recovery toward comparison levels during monitored abstinence. That tells us something significant: at least some of the biological changes associated with cannabinoid tolerance are reversible.

But reversibility doesn’t mean every person recovers at the same speed, and it certainly doesn’t mean every effect of THC develops tolerance equally.

Not Every Effect Develops Tolerance the Same Way

This is where the subject becomes more interesting than simply saying, “Your receptors got used to it.”

Tolerance can develop differently across cannabinoid effects. A person might notice that the intoxicating effects of THC have diminished while other effects remain more noticeable. Changes in heart rate, cognition, subjective intoxication and other responses do not necessarily follow identical tolerance patterns.

The body’s response also depends on dose, frequency, duration, route of administration and individual physiology. Someone using THC occasionally isn’t necessarily experiencing the same receptor adaptations as someone using it multiple times every day.

And here’s something especially important for King Harvest: a reduced sensation of THC does not automatically mean reduced therapeutic activity, and increased intoxication does not automatically mean greater therapeutic benefit.

If someone is using cannabinoids for pain, sleep or another symptom, the meaningful question isn’t simply whether they still feel the product. It’s whether the original objective is being achieved, whether adverse effects have changed, and whether something else in their health or environment has shifted.

For example, someone experiencing more pain after several months of stable dosing may have developed cannabinoid tolerance. But their underlying condition might also have changed. Sleep disruption, inflammation, medication changes, stress or disease progression could all influence what they’re experiencing.

Increasing THC without understanding the reason for the change may address the wrong problem.

And sometimes the wrong problem gets rather expensive.

Why More Isn’t Always Better

There’s an understandable temptation to treat tolerance as a mathematical problem. If the response decreases, increase the input until the desired response returns.

Unfortunately, biological systems aren’t particularly interested in our spreadsheets.

Repeated dose escalation can increase exposure and adverse effects while potentially encouraging further tolerance. THC can impair attention, memory, coordination and reaction time, and higher doses can produce anxiety or other unwanted effects. Frequent use can also lead to physical dependence in some individuals, with withdrawal symptoms occurring after stopping.

Tolerance and dependence are related concepts, but they aren’t identical. Tolerance means a diminished response to repeated exposure. Physical dependence means the body has adapted such that stopping or reducing exposure can produce withdrawal symptoms. Neither automatically establishes cannabis use disorder, although frequent use and escalating doses deserve thoughtful assessment.

CBD adds another complication because it doesn’t behave like THC at CB1 receptors. Its pharmacology is different, and we shouldn’t assume that tolerance to THC automatically predicts tolerance to CBD or that adding CBD reliably reverses THC tolerance. Human evidence doesn’t support such simple formulas.

This is why cannabinoid medicine benefits from something considerably less exciting than chasing bigger numbers: periodically reassessing what the treatment is accomplishing.

The appropriate response might involve evaluating the original therapeutic goal, reviewing medications and health changes, reconsidering dose or frequency, or discussing whether a supervised adjustment is appropriate. Abruptly stopping or changing treatment isn’t necessarily suitable for every patient, particularly when other medications or serious illnesses are involved.

The Adaptive Human Strikes Again

There’s a larger lesson here that reaches well beyond cannabinoids.

We often interpret a diminishing response as evidence that something is wrong with the substance we’re using. But sometimes the diminishing response is evidence that biology has been doing exactly what it was designed to do: adjusting to repeated information.

The same nervous system that learns to ignore traffic outside the bedroom can become less responsive to a repeatedly administered drug. The same adaptive machinery that helps us function in a changing environment can make yesterday’s successful intervention less effective tomorrow.

That’s the fascinating contradiction at the center of this series. Adaptation can be both the solution and the problem, depending on what we’re asking biology to accomplish.

And it raises a question worth considering whenever a familiar dose stops producing familiar results: Are we dealing with a product problem, a change in the underlying condition, or a biological system that has adapted to repeated exposure?

Those possibilities deserve different responses.

Because the answer to a changing biological response isn’t always more of the same signal. Sometimes the smarter approach is understanding why the signal no longer means what it once did.

Nature doesn’t promise that yesterday’s solution will remain tomorrow’s solution.

Biology keeps adapting, whether we update our thinking or not.

The Biology

THC acts primarily as a partial agonist at cannabinoid CB1 and CB2 receptors. Repeated THC exposure can produce adaptations in CB1 signaling, including receptor desensitization and downregulation, contributing to tolerance. These adaptations differ across tissues, neural circuits, exposure patterns and measured outcomes.

Human PET imaging studies have demonstrated reduced brain CB1 receptor availability among chronic daily cannabis users, with evidence of recovery during abstinence. However, receptor availability is only one part of cannabinoid pharmacodynamics, and these findings don’t establish a universal timeline for tolerance reversal or predict the therapeutic response of every patient.

Tolerance, physical dependence and addiction are distinct concepts. Tolerance describes a reduced response to repeated exposure, while dependence involves physiological adaptation that may produce withdrawal upon discontinuation. Cannabis use disorder involves a broader pattern of impaired control and continued use despite harmful consequences.

Key Takeaway

When a familiar cannabinoid dose stops producing familiar results, the answer isn’t automatically to increase the amount. Repeated THC exposure can alter CB1 receptor signaling, but changes in symptoms, medications, health and individual circumstances may also explain a different response.

The dose may be unchanged, but the biology receiving it may have adapted.

Understanding that difference is the beginning of a more thoughtful approach to cannabinoid medicine.